What was the overall market valuation of the dyspepsia market in 2024?

The overall market valuation was 140.31 $ Million in 2024. Read More

What is the projected market valuation for the dyspepsia market by 2035?

The projected valuation for 2035 is 215.0 $ Million. Read More

What is the expected CAGR for the dyspepsia market during the forecast period 2025 - 2035?

The expected CAGR for the dyspepsia market during the forecast period 2025 - 2035 is 3.96 %. Read More

Which treatment type had the highest valuation in the dyspepsia market?

Proton Pump Inhibitors had the highest valuation, reaching between 50.0 $ Million and 80.0 $ Million. Read More

What are the key segments of the dyspepsia market based on type?

The key segments based on type include Functional Dyspepsia, Non-Ulcer Dyspepsia, and Organic Dyspepsia. Read More

How did the valuation of Functional Dyspepsia compare to Non-Ulcer Dyspepsia in 2024?

Functional Dyspepsia was valued at 56.12 $ Million, while Non-Ulcer Dyspepsia was valued at 42.09 $ Million. Read More

What distribution channel is expected to have the highest valuation in the dyspepsia market?

Retail Pharmacies are expected to have the highest valuation, projected between 60.0 $ Million and 90.0 $ Million. Read More

Which company is a key player in the dyspepsia market?

Pfizer Inc is one of the key players in the dyspepsia market. Read More

What route of administration had the highest valuation in the dyspepsia market?

The Oral route of administration had the highest valuation, ranging from 70.0 $ Million to 110.0 $ Million. Read More

What is the valuation range for Organic Dyspepsia in the dyspepsia market?

The valuation range for Organic Dyspepsia is between 42.1 $ Million and 62.3 $ Million. Read More

South Korea Dyspepsia Market

ID: MRFR/HC/54505-HCR

200 Pages

Rahul Gotadki

Last Updated: April 24, 2026

South Korea Dyspepsia Market Research Report: Size, Share, Trend Analysis By Types (Functional Dyspepsia, Non-Ulcer Dyspepsia, Organic Dyspepsia), By Treatment Type (Antacids, Proton Pump Inhibitors, H2-Receptor Antagonists, Prokinetics), By Route of Administration (Oral, Injectable, Topical) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035

South Korea Dyspepsia Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.96%

2024 Market Size$ 140.31 Million

2025 Market Size$ 145.87 Million

2035 Market Size$ 215 Million

Key Players

Pfizer Inc

GlaxoSmithKline plc

Boehringer Ingelheim GmbH

AstraZeneca plc

Novartis AG

Takeda Pharmaceutical Company Limited

Trends

Rising Awareness of Gastrointestinal Health
Technological Advancements in Treatment
Evolving Regulatory Landscape

Opportunities

Rising Healthcare Expenditure
Increasing Prevalence of Dyspepsia
Growing Interest in Herbal Remedies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Functional Dyspepsia
  2. 4.1.2 Non-Ulcer Dyspepsia
  3. 4.1.3 Organic Dyspepsia
2. 4.2 Construction, BY Treatment Type (USD Million)
  1. 4.2.1 Antacids
  2. 4.2.2 Proton Pump Inhibitors
  3. 4.2.3 H2-Receptor Antagonists
  4. 4.2.4 Prokinetics
3. 4.3 Construction, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Topical
4. 4.4 Construction, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GlaxoSmithKline plc (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim GmbH (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca plc (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi S.A. (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Johnson & Johnson (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

Functional Dyspepsia
Non-Ulcer Dyspepsia
Organic Dyspepsia

Construction By Treatment Type (USD Million, 2025-2035)

Antacids
Proton Pump Inhibitors
H2-Receptor Antagonists
Prokinetics

Construction By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Topical

Construction By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”